{"version":"1.0","provider_name":"Xspray","provider_url":"https:\/\/xspraypharma.com\/sv\/","author_name":"google@industritorget.se","author_url":"https:\/\/xspraypharma.com\/sv\/author\/googleindustritorget-se\/","title":"Xspray godk\u00e4nt f\u00f6r notering p\u00e5 Nasdaq First North - Xspray","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"MB62WnVSng\"><a href=\"https:\/\/xspraypharma.com\/sv\/pressmeddelande\/xspray-godkant-for-notering-pa-nasdaq-first-north\/\">Xspray godk\u00e4nt f\u00f6r notering p\u00e5 Nasdaq First North<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/xspraypharma.com\/sv\/pressmeddelande\/xspray-godkant-for-notering-pa-nasdaq-first-north\/embed\/#?secret=MB62WnVSng\" width=\"600\" height=\"338\" title=\"\u201dXspray godk\u00e4nt f\u00f6r notering p\u00e5 Nasdaq First North\u201d &ndash; Xspray\" data-secret=\"MB62WnVSng\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","description":"Xspray Pharma AB (publ) har som tidigare meddelats genomf\u00f6rt en nyemission inf\u00f6r planerad notering p\u00e5 Nasdaq First North. Nyemissionen inbringade cirka 132 miljoner kronor f\u00f6re emissionskostnader och Bolaget har efter transaktionen drygt 2\u00a0100 \u00e4gare. Granskningen av bolaget \u00e4r nu klar och Nasdaq har godk\u00e4nt Xspray Pharmas ans\u00f6kan om upptagande av aktierna till handel p\u00e5 First [&hellip;]"}